Wide Ranks

CTNM

Contineum Therapeutics, Inc.

14.77

Top Statistics
Market Cap 380 M Forward PE -9.12 Revenue Growth 0.00 %
Current Ratio 37.05 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.87 Enterprise / Revenue Price To Sales Trailing12 Months Infinity
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 213 M Total Cash Per Share 8.30 Total Debt 611000
Total Debt To Equity 0.2910 Current Ratio 37.05 Book Value Per Share 8.17
All Measures
Short Ratio 1168.00 % Message Board Id finmb_558548528 Shares Short Prior Month 952350
Return On Equity -0.2076 City San Diego Uuid 8c5df956-5bcb-360c-86d1-8cf5456d319f
Previous Close 14.53 First Trade Date Epoch Utc 1 B Book Value 8.17
Total Debt 611000 Volume 27183 Price To Book 1.81
Fifty Two Week Low 12.33 Total Cash Per Share 8.30 Shares Short Previous Month Date 1 B
Target Median Price 30.00 Max Age 86400 Recommendation Mean 1.50
Sand P52 Week Change 0.3133 Target Mean Price 29.25 Net Income To Common -28887000
Ask 14.96 Implied Shares Outstanding 25 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 73720 Average Volume10days 73720
Total Cash 213 M Next Fiscal Year End 1 B Held Percent Insiders 0.0619
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 14.53 Target Low Price 25.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 17.05 Open 14.59 Free Cashflow -22274876
State CA Dividend Yield 0.00 % Return On Assets -0.1532
Time Zone Short Name EST Trailing Eps -0.3600 Day Low 14.59
Address1 10578 Science Center Drive Shares Outstanding 19 M Price Hint 2
Target High Price 32.00 Website https://www.contineum-tx.com 52 Week Change -0.0409
Average Volume 79328 Forward Eps -1.84 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 3684.30 % Is_sp_500 False
Regular Market Day High 14.95 Profit Margins 0.00 % Debt To Equity 0.2910
Fifty Two Week High 22.00 Day High 14.95 Shares Short 1 M
Regular Market Open 14.59 Industry Key biotechnology Bid 14.65
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0406
Operating Cashflow -33347000 Currency USD Time Zone Full Name America/New_York
Market Cap 380 M Is_nasdaq_100 False Zip 92121
Quote Type EQUITY Industry Biotechnology Long Name Contineum Therapeutics, Inc.
Regular Market Day Low 14.59 Held Percent Institutions 0.7242 Current Price 14.77
Address2 Suite 200 Enterprise To Ebitda -3.87 Financial Currency USD
Current Ratio 37.05 Industry Disp Biotechnology Number Of Analyst Opinions 4
Country United States Float Shares 12 M Two Hundred Day Average 17.44
Enterprise Value 167 M Price To Sales Trailing12 Months Infinity Forward PE -9.12
Regular Market Volume 27183 Ebitda -43303000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.

Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).

The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.

Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.

The company was incorporated in 2009 and is headquartered in San Diego, California.